MyHealthChecked PLC Statement re. COVID-19 testing (2278M)

TIDMMHC

RNS Number : 2278M

MyHealthChecked PLC

20 September 2021

The ' Statement re. COVID-19 testing ' announcement for MyHealthChecked plc released on 17 September 2021 at 17:50 under RNS No 2130M has been re-released in the interests of market clarity.

The announcement text is unchanged and is reproduced in full below.

MyHealthChecked plc

( " MyHealthChecked " or " the Company " )

Statement re. COVID-19 testing

MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company, notes the recent Government statement regarding measures to simplify international travel.

As announced in the 7 July Trading update H1 revenues dramatically increased to GBP3.27m (H1 2020: GBP12,700) driven by COVID-19 testing services. This trend has continued into Q3 with monthly testing volumes exceeding those seen in the final two months of H1. Further information on Q3 trading will be provided in the results statement scheduled for Wednesday 29 September 2021.

Whilst the Government has announced the removal of Day 2 testing from an October date to be confirmed, the Directors remain confident that monthly testing volumes will remain a significant contributor to growth throughout the remainder of the financial year, even with levels naturally lower than the peak levels seen around summer holiday period. These revenues are still expected to contribute significantly to the results for the financial year ending 31 December 2021 and the Directors remain very optimistic about the business prospects for the full year.

The requirements surrounding PCR testing for out-bound travel, the "Fit to Fly" scheme, have not changed and Directors expect to see these volumes continuing. The Directors also expect that these newly announced changes to international travel will encourage more people to travel abroad from the UK, and that this will contribute to a rise in out-bound testing volumes.

As already stated, the Company's genomic testing service has been focussed on its COVID-19 testing offering, however it provides the foundation to create a wider portfolio of easy to use DNA tests over the longer-term. MyHealthChecked plc has a strong pipeline of genetic tests outside of COVID-19 to ensure long-term sustainable revenue growth.

For further information contact:

 
 MyHealthChecked plc                                                               www.myhealthchecked.com 
 P enny McCormick , Chief Executive                                                        via Walbrook PR 
  Officer 
 Gareth Davies, Chief Financial and 
  Operations Officer 
 
 SPARK Advisory Partners Limited (NOMAD)                                          Tel: +44 (0)20 3368 3550 
 Neil Baldwin 
 
 Oberon Capital Ltd (Broker)                                                      Tel: +44 (0)20 3179 5344 
 Mike Seabrook                                                          mikeseabrook@oberoninvestments.com 
 
 Walbrook PR Ltd (Media &                    Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com 
  IR) 
 Paul McManus / Alice Woodings                                       Mob: +44(0)7980 541 893 / +44 (0)7407 
                                                                                                   804 654

About MyHealthChecked PLC ( www.myhealthcheckedplc.com )

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.

MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the acquisition of The Genome Store in November 2020. The tests will be made available online, and would be viable for over the counter purchase.

The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

STREAFNNFDAFEAA

(END) Dow Jones Newswires

September 20, 2021 02:00 ET (06:00 GMT)

Concepta (LSE:CPT)
過去株価チャート
から 10 2024 まで 11 2024